| Bid | 1.81 |
| Market Cap | 8.09M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -1.14 |
| PE Ratio (ttm) | -1.58 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 1.84 |
| Volume | 4,760,504 |
| Avg. Volume (20D) | 3,122,722 |
| Open | 1.92 |
| Previous Close | 1.72 |
| Day's Range | 1.80 - 2.16 |
| 52-Week Range | 0.77 - 4.50 |
| Beta | undefined |
About SILO
Silo Pharma Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in formulations and drug delivery systems. The company's lead program, SPC-15, is an intranasal treatment ...
Analyst Forecast
According to 1 analyst ratings, the average rating for SILO stock is "Buy." The 12-month stock price forecast is $undefined, which is a decrease of NaN% from the latest price.
1 year ago · proactiveinvestors.com
Silo Pharma shares take off as anxiety and PTSD therapeutic candidate achieves milestoneSilo Pharma shares rose on Tuesday after the development stage biopharmaceutical company announced it has advanced the formulation development of its therapeutic candidate SPC-15, achieving a liquid n...
1 year ago · pennystocks.com
7 Top Penny Stocks To Watch With Big News This WeekPenny Stocks With News Light Up The Scanners This Week This week
